Skip to main content

Table 3 Clinical outcomes data by group

From: Effectiveness of saline water and lidocaine injection treatment of intractable plantar keratoma: a randomised feasibility study

 

Group 1

Group 2

Group 3

Group 4

Mean (SD)

Mean (SD)

Mean (SD)

Mean (SD)

n = 10 at baseline

n = 10 at baseline

n = 10 at baseline

n = 10 at baseline

VAS

Baseline

4.8

(2.1)

3.7

(2.0)

4.2

(2.9)

3.5

(3.0)

(0–10)

T2

1.9

(2.6)

1.7

(2.3)

1.0

(1.6)

1.7

(2.3)

 

T3

2.6

(3.0)

1.2

(2.1)

0.7

(1.3)

1.2

(2.3)

 

T4

2.8

(3.0)

0.2

(0.3)

0.6

(1.4)

1.2

(2.3)

 

T6

4.0

(3.6)

3.1

(3.0)

2.2

(3.1)

1.2

(2.3)

 

T12

5.3

(3.7)

1.8

(2.7)

2.2

(2.4)

2.7

(2.8)

FFI-R

Baseline

68.8

(17.1)

57.8

(29.4)

69.6

(34.7)

53.4

(29.6)

(/270)

T2

45.1

(20.9)

45.1

(26.2)

37.3

(25.8)

37.1

(22.9)

 

T3

51.1

(37.1)

30.1

(11.7)

32.4

(22.6)

32.6

(23.4)

 

T4

41.2

(23.7)

28.5

(13.7)

31.1

(24.8)

32.5

(23.4)

 

T6

54.1

(41.9)

34.4

(21.9)

46.3

(42.4)

31.9

(23.6)

 

T12

63.5

(48.5)

37.7

(22.9)

33.3

(14.0)

34.4

(22.7)

IPK’s Width

Baseline

3.4

(1.6)

3.3

(2.7)

3.1

(1.6)

2.0

(1.5)

(mm)

T2

2.8

(0.9)

2.1

(1.3)

2.8

(2.6)

2.1

(0.9)

 

T3

2.1

(0.9)

1.7

(1.5)

2.5

(3.4)

1.4

(1.4)

 

T4

2.1

(1.4)

1.9

(1.6)

0.9

(1.1)

1.4

(1.4)

IPK’s Length

Baseline

2.7

(1.0)

2.9

(2.7)

3.4

(2.2)

2.5

(1.5)

(mm)

T2

2.7

(1.0)

2.1

(1.6)

2.8

(2.6)

2.1

(1.2)

 

T3

2.5

(1.1)

1.9

(1.4)

3.0

(4.1)

1.6

(1.6)

 

T4

2.3

(1.5)

1.8

(1.4)

1.1

(1.5)

1.6

(1.6)

IPK’s Depth

Baseline

1.7

(0.7)

1.7

(0.8)

1.7

(0.6)

1.5

(0.9)

(mm)

T2

1.4

(0.5)

1.1

(0.9)

0.8

(0.4)

1.0

(0.7)

 

T3

0.9

(0.1)

0.8

(0.7)

0.3

(0.3)

0.7

(0.8)

 

T4

1.0

(0.7)

0.8

(0.6)

0.3

(0.4)

0.7

(0.8)

  1. VAS Visual analog scale; FFI-R Foot Function Index-Revised; IPK Intractable Plantar Keratoma; SD Standard Deviation; mm: millimeter; T2 intervention at 4-week; T3 intervention at 8-week; T4 intervention at 12-week; T6 6-month follow-up; T12 12-month follow-up